Compare PAGS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | CELC |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | PAGS | CELC |
|---|---|---|
| Price | $11.42 | $107.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $11.86 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 4.1M | 796.0K |
| Earning Date | 03-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 16.68 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,662,823,389.00 | N/A |
| Revenue This Year | $14.75 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $6.70 | $7.58 |
| 52 Week High | $12.32 | $120.32 |
| Indicator | PAGS | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 49.74 |
| Support Level | $10.53 | $103.92 |
| Resistance Level | $11.90 | $111.00 |
| Average True Range (ATR) | 0.51 | 6.00 |
| MACD | -0.04 | -1.04 |
| Stochastic Oscillator | 58.31 | 23.68 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.